Re: Research on Samter's in Boston

[Guest guest]

Very interesting! Please keep us posted on anything more you learn about this research!

Jane

From: maria.ashley30 <maria.ashley30@...>Subject: Research on Samter's in Bostonsamters Date: Friday, May 13, 2011, 9:19 AM

Am new to the group, and new to the diagnosis, though have learned a lot from reading the many posts. Thank you all for the comments. I just found out that the doctors at Brigham and Women's Hospital are doing research for patients with Samter's Triad in Boston. Right now they are just collecting blood samples for patients who are doing aspirin desensitization, but I think they are going to start doing a clinical trial with a new drug for treatment in the fall. I couldn't find anyone else in the area who was doing any work at all on this disease.

[Guest guest]

Can you provide a contact? We may be interested in participating.

Thanks.

>

> Am new to the group, and new to the diagnosis, though have learned a lot from

reading the many posts. Thank you all for the comments. I just found out that

the doctors at Brigham and Women's Hospital are doing research for patients with

Samter's Triad in Boston. Right now they are just collecting blood samples for

patients who are doing aspirin desensitization, but I think they are going to

start doing a clinical trial with a new drug for treatment in the fall. I

couldn't find anyone else in the area who was doing any work at all on this

disease.

>

[Guest guest]

Thank you for the information. I wonder if this forthcoming trial is from

Dr Drazen of Brigham's, who wrote a good article about the genetics of Samter's

a few years ago. Could anyone in the group who has contact with Brigham's let us

know what they intend to test when they get the info ?

>

> Am new to the group, and new to the diagnosis, though have learned a lot from

reading the many posts. Thank you all for the comments. I just found out that

the doctors at Brigham and Women's Hospital are doing research for patients with

Samter's Triad in Boston. Right now they are just collecting blood samples for

patients who are doing aspirin desensitization, but I think they are going to

start doing a clinical trial with a new drug for treatment in the fall. I

couldn't find anyone else in the area who was doing any work at all on this

disease.

>

[Guest guest]

I think it's Laidlaw in the allergy department, but I have an appointment there on Thursday, so I'll ask around

samters From: asfyso@...Date: Sun, 15 May 2011 19:37:28 +0000Subject: Re: Research on Samter's in Boston

Thank you for the information. I wonder if this forthcoming trial is from Dr Drazen of Brigham's, who wrote a good article about the genetics of Samter's a few years ago. Could anyone in the group who has contact with Brigham's let us know what they intend to test when they get the info ?>> Am new to the group, and new to the diagnosis, though have learned a lot from reading the many posts. Thank you all for the comments. I just found out that the doctors at Brigham and Women's Hospital are doing research for patients with Samter's Triad in Boston. Right now they are just collecting blood samples for patients who are doing aspirin desensitization, but I think they are going to start doing a clinical trial with a new drug for treatment in the fall. I couldn't find anyone else in the area who was doing any work at all on this disease.>

[Guest guest]

Thank you for keeping us posted on what you learn. I really appreciate it!JaneFrom: alexandra rubin <arub4378@...>Subject: RE: Re: Research on Samter's in Bostonsamters Date: Tuesday, May 17, 2011, 3:11 PM

I think it's Laidlaw in the allergy department, but I have an appointment there on Thursday, so I'll ask around

samters From: asfyso@...Date: Sun, 15 May 2011 19:37:28 +0000Subject: Re: Research on Samter's in Boston

Thank you for the information. I wonder if this forthcoming trial is from Dr Drazen of Brigham's, who wrote a good article about the genetics of Samter's a few years ago. Could anyone in the group who has contact with Brigham's let us know what they intend to test when they get the info ?>> Am new to the group, and new to the diagnosis, though have learned a lot from reading the many posts. Thank you all for the comments. I just found out that the doctors at Brigham and Women's Hospital are doing research for patients with Samter's Triad in Boston. Right now they are just collecting blood samples for patients who are doing aspirin desensitization, but I think they are going to start doing a clinical trial with a new drug

for treatment in the fall. I couldn't find anyone else in the area who was doing any work at all on this disease.>

[Guest guest]



I was desensitized by Dr Laidlaw in September. I have posted this information before, but here it is again. I highly recommend you contact her. Feel free to email too and let her know you found out about her on this group. You can mention my name as well. Good luck

Stacey Sutela

M. Laidlaw, MDDepartment of Allergy/ImmunologyBrigham and Women's Hospital, Boston MALaboratory Office: 617-525-1238Outpatient Clinic: 617-732-9850tlaidlaw@...

Re: Research on Samter's in Boston

Thank you for the information. I wonder if this forthcoming trial is from Dr Drazen of Brigham's, who wrote a good article about the genetics of Samter's a few years ago. Could anyone in the group who has contact with Brigham's let us know what they intend to test when they get the info ?>> Am new to the group, and new to the diagnosis, though have learned a lot from reading the many posts. Thank you all for the comments. I just found out that the doctors at Brigham and Women's Hospital are doing research for patients with Samter's Triad in Boston. Right now they are just collecting blood samples for patients who are doing aspirin desensitization, but I think they are going to start doing a clinical trial with a new drug for treatment in the fall. I couldn't find anyone else in the area who was doing any work at all on this disease.>

[Guest guest]

Thank you andra ; Dr Laidlaw has co-authored a couple of articles on

leukotrienes and prostaglandins, it will be interesting to see what she plans to

try.

> >

> > Am new to the group, and new to the diagnosis, though have learned a lot

from reading the many posts. Thank you all for the comments. I just found out

that the doctors at Brigham and Women's Hospital are doing research for patients

with Samter's Triad in Boston. Right now they are just collecting blood samples

for patients who are doing aspirin desensitization, but I think they are going

to start doing a clinical trial with a new drug for treatment in the fall. I

couldn't find anyone else in the area who was doing any work at all on this

disease.

> >

>

[Guest guest]

I was at Brigham today. I spoke with Dr. na Castells and she said that Dr. Laidlaw is going to start doing a research study. It would involve an aspirin challenge, desensitization, and then adding a drug similar to plavix to the aspirin regiment to enhance the effect of the aspirin. samters From: sutela@...Date: Tue, 17 May 2011 20:01:58 -0400Subject: Re: Re: Research on Samter's in Boston  I was desensitized by Dr Laidlaw in September. I have posted this information before, but here it is again. I highly recommend you contact her. Feel free to email too and let her know you found out about her on this group. You can mention my name as well. Good luckStacey Sutela M. Laidlaw, MDDepartment of Allergy/ImmunologyBrigham and Women's Hospital, Boston MALaboratory Office: 617-525-1238Outpatient Clinic: 617-732-9850tlaidlaw@... Re: Research on Samter's in Boston Thank you for the information. I wonder if this forthcoming trial is from Dr Drazen of Brigham's, who wrote a good article about the genetics of Samter's a few years ago. Could anyone in the group who has contact with Brigham's let us know what they intend to test when they get the info ?>> Am new to the group, and new to the diagnosis, though have learned a lot from reading the many posts. Thank you all for the comments. I just found out that the doctors at Brigham and Women's Hospital are doing research for patients with Samter's Triad in Boston. Right now they are just collecting blood samples for patients who are doing aspirin desensitization, but I think they are going to start doing a clinical trial with a new drug for treatment in the fall. I couldn't find anyone else in the area who was doing any work at all on this disease.>

[Guest guest]

Thanks andra.

Plavix (clopidrogel) plus aspirin against Samter's ?! This combination is what

is normally used to thin blood after a heart attack.

If this other drug is really like Plavix, ie a platelet antiaggregant, it could

increase the long-term risk of hemorrhage.

The only expected benefit I can see from the literature is that it may reduce

the leukotriene inflammation caused by germs and may reduce fibrosis.

Platelets. 2009 Feb;20(1):50-7.

Anti-platelet drugs and outcome in severe infection: clinical impact and

underlying mechanisms.

Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, Claus RA,

Bauer M, Lösche W.

Source

Anaesthesiology and Intensive Care Medicine, University Hospital Jena, Jena,

Germany.

Abstract

Platelet activation contributes to microvascular thrombosis and organ failure in

systemic inflammation. We tested the hypothesis whether anti-platelet drugs

might favourably affect outcome in patients at risk for organ failure as well as

in a mouse model of endotoxin shock. Two hundred twenty-four consecutive

patients who were admitted for community acquired pneumonia over a time period

of 5 years to a University Hospital were enrolled; about 20% of whom received

anti-platelet drugs (acetylsalicylic acid, thienopyridines) for secondary

prevention of cardiovascular disease. Patients with anti-platelet drugs were

about 12 years old but did not differ in SOFA score and routine laboratory

parameters at admission. Logistic regression and 2 x 2 table analysis in

age-matched subgroups indicated that anti-platelet drugs may reduce the need of

intensive care treatment (odds ratio (OR) 0.32 [95% confidential interval:

0.10-1.00] and 0.19 [0.04-0.87], respectively). In age-matched subgroups, the

use of anti-platelet drugs was also associated with a shorter stay in hospital

(13.9 +/- 6.2 vs. 18.2 +/- 10.2 days; p < 0.02). In the animal model Balb/c mice

were pre-treated with clopidogrel (added to drinking water) for 4 days prior to

intraperitoneal (i.p.) administration of endotoxin (lipopolsaccharide (LPS) from

Escherichia coli 0111:B4). Within the first 48 hours after LPS there were no

differences between clopidogrel and control animals (n = 26 each) in

macro-haemodynamics. However, clopidogrel abolished the LPS-induced drop in

platelet count and reduced fibrin deposition in lung tissue. Using DNA

microarray technology, we could show that clopidogrel suppressed

endotoxin-induced up-regulation of inflammation-relevant genes, including

arachidonate-5-lipoxygenase activating protein and leukotriene B4 receptor 1.

According to our data a possible benefit of anti-platelet drugs in patients on

risk for systemic inflammation and organ failure should be tested in a

prospective trial.

> >

> > Am new to the group, and new to the diagnosis, though have learned a lot

from reading the many posts. Thank you all for the comments. I just found out

that the doctors at Brigham and Women's Hospital are doing research for patients

with Samter's Triad in Boston. Right now they are just collecting blood samples

for patients who are doing aspirin desensitization, but I think they are going

to start doing a clinical trial with a new drug for treatment in the fall. I

couldn't find anyone else in the area who was doing any work at all on this

disease.

> >

>

[Guest guest]

I would have concerns about the combination of aspirin and plavix. Hopefully

she'll be monitoring the dosages and taking frequent blood tests. I guess

we'll never know until somebody tries it. But I still would be hesitant in

taking a combination of these drugs as part of a long-term treatment.

Re: Research on Samter's in Boston

Thanks andra.

Plavix (clopidrogel) plus aspirin against Samter's ?! This combination is

what is normally used to thin blood after a heart attack.

If this other drug is really like Plavix, ie a platelet antiaggregant, it

could increase the long-term risk of hemorrhage.

The only expected benefit I can see from the literature is that it may

reduce the leukotriene inflammation caused by germs and may reduce fibrosis.

Platelets. 2009 Feb;20(1):50-7.

Anti-platelet drugs and outcome in severe infection: clinical impact and

underlying mechanisms.

Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M, Deigner HP, Claus RA,

Bauer M, Lösche W.

Source

Anaesthesiology and Intensive Care Medicine, University Hospital Jena, Jena,

Germany.

Abstract

Platelet activation contributes to microvascular thrombosis and organ

failure in systemic inflammation. We tested the hypothesis whether

anti-platelet drugs might favourably affect outcome in patients at risk for

organ failure as well as in a mouse model of endotoxin shock. Two hundred

twenty-four consecutive patients who were admitted for community acquired

pneumonia over a time period of 5 years to a University Hospital were

enrolled; about 20% of whom received anti-platelet drugs (acetylsalicylic

acid, thienopyridines) for secondary prevention of cardiovascular disease.

Patients with anti-platelet drugs were about 12 years old but did not differ

in SOFA score and routine laboratory parameters at admission. Logistic

regression and 2 x 2 table analysis in age-matched subgroups indicated that

anti-platelet drugs may reduce the need of intensive care treatment (odds

ratio (OR) 0.32 [95% confidential interval: 0.10-1.00] and 0.19 [0.04-0.87],

respectively). In age-matched subgroups, the use of anti-platelet drugs was

also associated with a shorter stay in hospital (13.9 +/- 6.2 vs. 18.2 +/-

10.2 days; p < 0.02). In the animal model Balb/c mice were pre-treated with

clopidogrel (added to drinking water) for 4 days prior to intraperitoneal

(i.p.) administration of endotoxin (lipopolsaccharide (LPS) from Escherichia

coli 0111:B4). Within the first 48 hours after LPS there were no differences

between clopidogrel and control animals (n = 26 each) in

macro-haemodynamics. However, clopidogrel abolished the LPS-induced drop in

platelet count and reduced fibrin deposition in lung tissue. Using DNA

microarray technology, we could show that clopidogrel suppressed

endotoxin-induced up-regulation of inflammation-relevant genes, including

arachidonate-5-lipoxygenase activating protein and leukotriene B4 receptor

1. According to our data a possible benefit of anti-platelet drugs in

patients on risk for systemic inflammation and organ failure should be

tested in a prospective trial.

> >

> > Am new to the group, and new to the diagnosis, though have learned a lot

from reading the many posts. Thank you all for the comments. I just found

out that the doctors at Brigham and Women's Hospital are doing research for

patients with Samter's Triad in Boston. Right now they are just collecting

blood samples for patients who are doing aspirin desensitization, but I

think they are going to start doing a clinical trial with a new drug for

treatment in the fall. I couldn't find anyone else in the area who was doing

any work at all on this disease.

> >

>

------------------------------------

[Guest guest]

On the subject of experimental treatments has anyone seen any

reports of using Lasix (furosemide) either orally or as an inhaled

medication?

On 5/19/2011 3:57 PM, asfy wrote:

Thanks andra.

Plavix (clopidrogel) plus aspirin against Samter's ?! This

combination is what is normally used to thin blood after a

heart attack.

If this other drug is really like Plavix, ie a platelet

antiaggregant, it could increase the long-term risk of

hemorrhage.

The only expected benefit I can see from the literature is

that it may reduce the leukotriene inflammation caused by

germs and may reduce fibrosis.

Platelets. 2009 Feb;20(1):50-7.

Anti-platelet drugs and outcome in severe infection:

clinical impact and underlying mechanisms.

Winning J, Reichel J, Eisenhut Y, Hamacher J, Kohl M,

Deigner HP, Claus RA, Bauer M, Lösche W.

Source

Anaesthesiology and Intensive Care Medicine, University

Hospital Jena, Jena, Germany.

Abstract

Platelet activation contributes to microvascular

thrombosis and organ failure in systemic inflammation. We

tested the hypothesis whether anti-platelet drugs might

favourably affect outcome in patients at risk for organ

failure as well as in a mouse model of endotoxin shock.

Two hundred twenty-four consecutive patients who were

admitted for community acquired pneumonia over a time

period of 5 years to a University Hospital were enrolled;

about 20% of whom received anti-platelet drugs

(acetylsalicylic acid, thienopyridines) for secondary

prevention of cardiovascular disease. Patients with

anti-platelet drugs were about 12 years old but did not

differ in SOFA score and routine laboratory parameters at

admission. Logistic regression and 2 x 2 table analysis in

age-matched subgroups indicated that anti-platelet drugs

may reduce the need of intensive care treatment (odds

ratio (OR) 0.32 [95% confidential interval: 0.10-1.00] and

0.19 [0.04-0.87], respectively). In age-matched subgroups,

the use of anti-platelet drugs was also associated with a

shorter stay in hospital (13.9 +/- 6.2 vs. 18.2 +/- 10.2

days; p < 0.02). In the animal model Balb/c mice were

pre-treated with clopidogrel (added to drinking water) for

4 days prior to intraperitoneal (i.p.) administration of

endotoxin (lipopolsaccharide (LPS) from Escherichia coli

0111:B4). Within the first 48 hours after LPS there were

no differences between clopidogrel and control animals (n

= 26 each) in macro-haemodynamics. However, clopidogrel

abolished the LPS-induced drop in platelet count and

reduced fibrin deposition in lung tissue. Using DNA

microarray technology, we could show that clopidogrel

suppressed endotoxin-induced up-regulation of

inflammation-relevant genes, including

arachidonate-5-lipoxygenase activating protein and

leukotriene B4 receptor 1. According to our data a

possible benefit of anti-platelet drugs in patients on

risk for systemic inflammation and organ failure should be

tested in a prospective trial.

> >

> > Am new to the group, and new to the diagnosis,

though have learned a lot from reading the many posts.

Thank you all for the comments. I just found out that the

doctors at Brigham and Women's Hospital are doing research

for patients with Samter's Triad in Boston. Right now they

are just collecting blood samples for patients who are

doing aspirin desensitization, but I think they are going

to start doing a clinical trial with a new drug for

treatment in the fall. I couldn't find anyone else in the

area who was doing any work at all on this disease.

> >

>

[Guest guest]

Carl,I think this 2003 paper is the last one published :Arch Otolaryngol Head Neck Surg. 2003 Jun;129(6):656-9.Treatment of recurrent chronic hyperplastic sinusitis with nasal polyposis.Passàli D, Bernstein JM, Passali FM, Damiani V, Passàli GC, Bellussi L.SourceENT Department, University of Siena Medical School, Siena, Italy. Passali@...AbstractOBJECTIVE:To demonstrate the long-term efficacy of intranasal furosemide, an inhibitor of the sodium chloride cotransporter channel at the basolateral surface of the respiratory epithelial cell, vs no therapeutic intervention vs intranasal mometasone furoate, a corticosteroid, in preventing relapses of chronic hyperplastic sinusitis with nasal polyposis.DESIGN:Randomized prospective controlled study. Patients were examined every 6 months during follow-up (range, 1-9 years).PATIENTS:One hundred seventy patients with bilateral obstructive or minimally obstructive chronic hyperplastic sinusitis with nasal polyposis.INTERVENTION:All patients were surgically treated in the ENT Department, University of Siena Medical School. One month after surgery, group 1 patients (n = 97) started treatment with intranasal furosemide, group 2 (n = 40) received no therapeutic treatment, and group 3 (n = 33) were treated with mometasone.MAIN OUTCOME MEASURES:Clinical and instrumental evaluation of postoperative outcomes.RESULTS:Seventeen (17.5%) of 97 patients in group 1, 12 (30.0%) of 40 patients in group 2, and 8 (24.2%) of 33 patients in group 3 experienced nasal polyposis relapses. We noted a prevalence of early-stage relapse in patients treated with furosemide or mometasone, whereas patients who did not receive any treatment experienced more severe grades of chronic hyperplastic sinusitis with nasal polyposis (P<.005).CONCLUSION:Use of intranasal furosemide represents a valid therapeutic treatment in the prevention of chronic hyperplastic sinusitis with nasal polyposis.> > > >> > > > Am new to the group, and new to the diagnosis, though have learned > > a lot from reading the many posts. Thank you all for the comments. I > > just found out that the doctors at Brigham and Women's Hospital are > > doing research for patients with Samter's Triad in Boston. Right now > > they are just collecting blood samples for patients who are doing > > aspirin desensitization, but I think they are going to start doing a > > clinical trial with a new drug for treatment in the fall. I couldn't > > find anyone else in the area who was doing any work at all on this > > disease.> > > >> > >> >> >>

[Guest guest]

Asfy,

Thanks. Interesting and I will try to seek the original paper.

Carl